Wall Street brokerages predict that Heron Therapeutics Inc (NASDAQ:HRTX) will post ($0.95) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Heron Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.04) and the highest estimate coming in at ($0.78). Heron Therapeutics posted earnings of ($1.17) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 18.8%. The business is scheduled to issue its next earnings report on Monday, August 14th.

According to Zacks, analysts expect that Heron Therapeutics will report full-year earnings of ($3.71) per share for the current financial year, with EPS estimates ranging from ($4.15) to ($3.18). For the next year, analysts forecast that the firm will post earnings of ($2.26) per share, with EPS estimates ranging from ($3.91) to ($1.25). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that follow Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Wednesday, May 10th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by $0.06. The firm had revenue of $3.63 million during the quarter, compared to analysts’ expectations of $1.96 million. Heron Therapeutics had a negative net margin of 1,385.71% and a negative return on equity of 499.00%.

HRTX has been the topic of a number of research analyst reports. Jefferies Group LLC reiterated a “buy” rating and issued a $29.00 price target on shares of Heron Therapeutics in a report on Monday, April 10th. Cowen and Company reiterated a “buy” rating and issued a $40.00 price target on shares of Heron Therapeutics in a report on Friday, May 26th. Noble Financial reiterated a “buy” rating on shares of Heron Therapeutics in a report on Friday, May 12th. Cantor Fitzgerald reiterated a “buy” rating and issued a $31.00 price target (up previously from $30.00) on shares of Heron Therapeutics in a report on Thursday, May 11th. Finally, Aegis reiterated a “buy” rating and issued a $33.00 price target on shares of Heron Therapeutics in a report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating and eleven have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $31.00.

COPYRIGHT VIOLATION NOTICE: This story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/07/0-95-earnings-per-share-expected-for-heron-therapeutics-inc-nasdaqhrtx-this-quarter.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in HRTX. Legal & General Group Plc raised its position in shares of Heron Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 2,383 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Heron Therapeutics by 7.4% in the second quarter. Bank of New York Mellon Corp now owns 204,857 shares of the biotechnology company’s stock valued at $2,837,000 after buying an additional 14,086 shares in the last quarter. State of Wisconsin Investment Board bought a new position in shares of Heron Therapeutics during the second quarter valued at $457,000. Rubric Capital Management LP raised its position in shares of Heron Therapeutics by 6.3% in the second quarter. Rubric Capital Management LP now owns 1,700,000 shares of the biotechnology company’s stock valued at $23,545,000 after buying an additional 100,000 shares in the last quarter. Finally, Rhumbline Advisers raised its position in shares of Heron Therapeutics by 14.1% in the second quarter. Rhumbline Advisers now owns 50,630 shares of the biotechnology company’s stock valued at $701,000 after buying an additional 6,249 shares in the last quarter.

Shares of Heron Therapeutics (NASDAQ HRTX) remained flat at $16.15 during mid-day trading on Monday. 17,733 shares of the company were exchanged. Heron Therapeutics has a 52-week low of $12.21 and a 52-week high of $24.00. The firm has a 50-day moving average of $15.04 and a 200 day moving average of $14.44.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.